Drug intelligence / Profile preview

KK2260

Development stage: Phase 1
Lead developer: Kyowa Kirin
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KK2260 is a bispecific antibody developed by Kyowa Kirin for the treatment of advanced or metastatic solid tumors. It targets both the epidermal growth factor receptor (EGFR) and transferrin receptor protein 1 (TfR1), functioning as an antagonist to both receptors. By simultaneously inhibiting EGFR and TfR1, KK2260 aims to disrupt tumor cell proliferation and survival pathways that are commonly upregulated in various cancers. The drug is currently being evaluated in Phase 1 clinical trials for indications including esophageal squamous cell carcinoma, metastatic solid tumors, and squamous cell carcinoma of the head and neck[2][7].

Targets

EGFR (Epidermal growth factor receptor)TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on KK2260.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KK2260.

Explore the full profile